Drug Profile


Alternative Names: KADT-F10

Latest Information Update: 20 Mar 2007

Price : $50

At a glance

  • Originator Photochemical Company
  • Class Porphyrins; Radiosensitisers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Nov 2003 Preclinical trials in Cancer in Japan (unspecified route)
  • 03 Nov 2003 KADT F10 is available for licensing (http://www.optic.or.jp/com/pcc/pcc_e.html)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top